StageIPO | IPO
Date of IPO7/28/2022
INNOVITA (688253.SH) focuses on research and development, manufacturing, marketing, and after-sales service of In-vitro diagnostic tests. The company's technologies and products include antigen and antibody preparation, virus culture, colloidal gold, enzyme-linked immunosorbent assay, fluorescence immunoassay, and PCR. The company's biological products cover prenatal and postnatal care and sexually transmitted diseases series, respiratory virus series, digestive tract virus series, infectious disease series, and other testing fields. The company was founded in 2006 and is based in Beijing, China.
Missing: INNOVITA's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: INNOVITA's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing INNOVITA
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
INNOVITA is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Latest INNOVITA News
Sep 1, 2022
China News, Data, Media Intelligence and Insights Search for: Covid-19 In-Vitro Diagnostics Market 2022 key developmental strategies implemented by the key players:Cellex, Mayo Clinic Laboratories, BioMedomics, Abbott, Safecare Bio-Tech, Roche, Mount Sinai Laboratory, Henry Schein, BD, Chembio Diagnostics, Guangdong Hecin-Scientific, Ortho Clinical Diagnostics, Dynamiker Biotechnology (Tianjin), Guangzhou Wondfo Biotech, Zhejiang Orient Gene Biotech, ADVAITE, Innovita Biological Technology Source: Key Topics in this News Article: News Snapshot: News The Covid-19 In-Vitro Diagnostics market is globally one of the leading markets involving innovative techniques development and extremely categorized sector. After a thorough investigation conducted over the industries under Covid-19 In-Vitro Diagnostics market, the market report delivers in-depth information, based on the data related to export and import along with the ongoing industry trends in the global market. The report deeply observes the competitive structure of the Covid-19 In-Vitro Diagnostics market worldwide. The Covid-19 In-Vitro Diagnostics market report comprises the detailed summary of the various firms, manufacturers, organizations, and other competitive players that hold major count over the global...
INNOVITA Frequently Asked Questions (FAQ)
When was INNOVITA founded?
INNOVITA was founded in 2006.
Where is INNOVITA's headquarters?
INNOVITA's headquarters is located at 1st-2nd Floor, Building 6, No.1 Yuan, Haiying Road, Beijing.
What is INNOVITA's latest funding round?
INNOVITA's latest funding round is IPO.
Who are the investors of INNOVITA?
Investors of INNOVITA include BGI Cowin, AC Capital, Anrong Investment, Sequoia Capital China, bioVENTURE and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.